Recent events
Recent events tied to this brand in public sources.
Back to profile8 entries
2026
FDA approves Inovio treatment for rare throat disease
The US FDA approved Inovio's treatment for a rare throat disease.
2021
INOVIO and Colombia sign a collaboration MOU
INOVIO announced that it had signed a non-binding memorandum of understanding with Colombia's Ministry of Health and Social Protection to establish a framework for exploring knowledge sharing, technology licensing, and capacity building related to vaccines and other biopharmaceuticals in Colombia.
2021
Inovio and Advaccine expand vaccine-study partnership
Inovio Pharmaceuticals expanded its partnership with Advaccine Biopharmaceuticals to conduct a late-stage trial of its COVID-19 vaccine candidate. The expanded deal gives Advaccine rights to additional Asian countries outside Greater China, and the companies expect to share the trial costs equally.
2021
INOVIO and Advaccine expand partnership for global Phase 3 trial
INOVIO and Advaccine announced an expansion of their partnership to jointly conduct a global Phase 3 segment of the INO-4800 COVID-19 vaccine trial. The trial was planned to begin that summer and to be conducted primarily in Latin America and Asia.
2021
INOVIO prices public offering of common stock
INOVIO announced the pricing of an underwritten public offering of 17.7 million common shares at $8.50 per share. The company said gross proceeds were expected to be approximately $150.5 million before expenses, excluding any exercise of the underwriters’ option.
2021
Inovio and Advaccine enter China licensing agreement for INO-4800
Inovio entered a licensing agreement with Advaccine for manufacturing and selling its INO-4800 vaccine candidate in China. Advaccine received exclusive rights in China.
2020
INOVIO and Thermo Fisher sign vaccine manufacturing letter of intent
INOVIO announced that Thermo Fisher Scientific had signed a letter of intent to manufacture INOVIO's INO-4800 COVID-19 vaccine candidate, including drug-substance production and fill-and-finish work at US facilities.
2020
INOVIO works with IVI and KNIH on South Korean vaccine trial
CEPI granted $6.9 million in funding to INOVIO to work with the International Vaccine Institute and Korea National Institute of Health on a Phase 1/2 clinical trial of INOVIO’s COVID-19 vaccine candidate, INO-4800, in South Korea.